Macquarie Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Macquarie Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-9,750	Closed	-$437K	–	2504
2017 Q3	$437K	Buy	9,750 +1,450	+17%	+$49.4K	﹤0.01%	1488
2017 Q2	$248K	Buy	+8,300	New	+$205K	﹤0.01%	1398
2017 Q1	–	Sell	-28,349	Closed	-$534K	–	1593
2016 Q4	$534K	Sell	28,349 -64,817	-70%	-$1.59M	﹤0.01%	1303
2016 Q3	$2.8M	Sell	93,166 -6,001	-6%	-$187K	0.01%	873
2016 Q2	$3.81M	Buy	99,167 +45,517	+85%	+$1.89M	0.01%	780
2016 Q1	$2.04M	Buy	+53,650	New	+$1.87M	﹤0.01%	948

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Macquarie Group's JUNO Position: Q4 2017 in Review

Macquarie Group sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2017, closing a stake of 9,750 shares — an estimated $437K sold.

Macquarie Group first reported a position in JUNO in Q1 2016 and held it in 6 quarters. The position peaked at $3.81M in Q2 2016. 238 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

Macquarie Group reported no remaining Juno Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Macquarie Group sold 9,750 Juno Therapeutics, Inc. shares in Q4 2017, an estimated $437K.
Macquarie Group first reported a position in Juno Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
Macquarie Group's Juno Therapeutics, Inc. position peaked at $3.81M in Q2 2016.
238 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Macquarie Group's 13F filing for Q4 2017, filed 15 Feb 2018.